Business Day (1 July 2024) reported that Life Healthcare’s subsidiary, Life Molecular Imaging (LMI), has successfully sub-licensed its early-stage novel radiotherapeutic and radio diagnostic products (RM2) to the US-based Lantheus Holdings. This follows Life Healthcare’s decision to retain LMI within its portfolio after selling Alliance Medical Group for R21bn. Under the terms of the agreement, Lantheus will pay an upfront fee of $35m (approximately R650 million) for the sub-licensing rights.